1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → 5-(2,6-Dichloro-phenylmethanesulfonyl)-3-[1-{3,5-dimethyl-4-[2-oxo-2-((s)-3-pyrrolidin-1-ylmethyl-piperidin-1-yl)-ethyl]-1h-pyrrol-2-yl}-meth-(z)-ylidene]-1,3-dihydro-indol-2-one
反応式
[Cl:1][C:2]1[CH:7]=[CH:6][CH:5]=[C:4]([Cl:8])[C:3]=1[CH2:9][S:10]([C:13]1[CH:14]=[C:15]2[C:19](=[CH:20][CH:21]=1)[NH:18][C:17](=[O:22])/[C:16]/2=[CH:23]\[C:24]1[NH:28][C:27]([CH3:29])=[C:26]([CH2:30][C:31](O)=[O:32])[C:25]=1[CH3:34])(=[O:12])=[O:11].C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.[N:56]1([CH2:61][C@@H:62]2[CH2:67][CH2:66][CH2:65][NH:64][CH2:63]2)[CH2:60][CH2:59][CH2:58][CH2:57]1>CN(C=O)C>[Cl:8][C:4]1[CH:5]=[CH:6][CH:7]=[C:2]([Cl:1])[C:3]=1[CH2:9][S:10]([C:13]1[CH:14]=[C:15]2[C:19](=[CH:20][CH:21]=1)[NH:18][C:17](=[O:22])/[C:16]/2=[CH:23]\[C:24]1[NH:28][C:27]([CH3:29])=[C:26]([CH2:30][C:31](=[O:32])[N:64]2[CH2:65][CH2:66][CH2:67][C@@H:62]([CH2:61][N:56]3[CH2:57][CH2:58][CH2:59][CH2:60]3)[CH2:63]2)[C:25]=1[CH3:34])(=[O:12])=[O:11]参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
A mixture of {5-[5-(2,6-dichloro-phenylmethanesulfonyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-acetic acid (156 mg, 0.3 mmol), HOBt (80 mg) and EDAC (110 mg) in DMF (4 mL) was added TEA (3 drops). After stirring at rt for 2 hours, to the mixture was added (R)-3-pyrrolidin-1-ylmethyl-piperidine (250 mg). After stirring at rt for overnight, the reaction was concentrated and dissolved in ethyl acetate. It was then washed with water and sodium bicarbonate, dried and concentrated. The residue was purified on a silica gel column to give 172 mg of the titled compound. MS m/z 667 [M−1].
後処理
- stirringAfter stirring at rt for overnight
- concentrationthe reaction was concentrated
- dissolutiondissolved in ethyl acetate
- washIt was then washed with water and sodium bicarbonate
- customdried
- concentrationconcentrated
- customThe residue was purified on a silica gel column
出典と根拠
- ORDレコード
- ord-c8e3791ac7904ebf8f75effd224959a1
- 出典データセット
- uspto-grants-2003_07
- 特許番号
- US06599902B2
反応ノート
読み込み中…